Friday, July 10, 2026

pharma · Chronic Hepatitis D Infection · Chronic Hepatitis Delta Infection

Blue Earth Diagnostics

Blue Earth Diagnostics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Magdalen Centre, The Oxford Science Park, Oxford, OX4 4GA, GB HQ
2014 Founded
120 Employees
EMA registrant Type
Company details
Status
Public
HQ
Magdalen Centre, The Oxford Science Park, Oxford, OX4 4GA, GB
Founded
2014
Employees
120
Programs
11
Drugs
12
Patents
0
Intelligence · Drug Pipeline

Blue Earth Diagnostics pipeline

Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Blue Earth Diagnostics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

12 compounds
  1. bulevirtide

    Antiinfectives for systemic use (J05)

    Antiinfectives for systemic use (J05) compound in Blue Earth Diagnostics's portfolio. Mechanism: Bile acid transporter inhibitor.

    Mechanism
    Bile acid transporter inhibitor
  2. Development asset linked to Blue Earth Diagnostics in public FDA and regional records.

  3. Development asset linked to Blue Earth Diagnostics in public FDA and regional records.

  4. Development asset linked to Blue Earth Diagnostics in public FDA and regional records.

  5. Development asset linked to Blue Earth Diagnostics in public FDA and regional records.

  6. Development asset linked to Blue Earth Diagnostics in public FDA and regional records.

  7. Various (V10) compound in Blue Earth Diagnostics's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent
  8. Development asset linked to Blue Earth Diagnostics in public FDA and regional records.

  9. Development asset linked to Blue Earth Diagnostics in public FDA and regional records.

  10. Development asset linked to Blue Earth Diagnostics in public FDA and regional records.

  11. Development asset linked to Blue Earth Diagnostics in public FDA and regional records.